MedDataX Logo

Kineret in the Treatment of Rheumatoid Arthritis

NCT ID: NCT02915094

Last Updated: 2017-08-11

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

30 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-10-31

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objective of the study is to gain knowledge about the administration of Kineret in patients with rheumatoid arthritis in the daily routine treatment and not in controlled trials. In the current survey, the investigation of the response rate of Kineret regarding the date of onset of action, the efficacy, as well as the tolerability and safety are of particular interest.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Anakinra (Kineret®) in Combination With Disease Modifying Anti-Rheumatic Drugs (DMARDS) in Subjects With Active Rheumatoid Arthritis (RA)

NCT00117091

Rheumatoid Arthritis
COMPLETED PHASE3

Long-term Safety Study of Kineret® in Patients With Systemic Juvenile Idiopathic Arthritis (SJIA)

NCT03932344

Still Disease, Juvenile Onset
COMPLETED

Long Term Efficacy, Safety and Immunogenicity of Enerceptan in Rheumatoid Arthritis ( GEMENE002 )

NCT03403140

Rheumatoid Arthritis
UNKNOWN PHASE3

Comparison of Two Etanercept Regimens (REUMATOCEPT® Versus ENBREL®) for Treatment of Rheumatoid Arthritis

NCT01394913

Rheumatoid Arthritis
WITHDRAWN PHASE3

A Study to Evaluate Efficacy and Safety of Anakinra in the Treatment of Still's Disease (SJIA and AOSD)

NCT03265132

Still's Disease, Adult-Onset Still's Disease, Juvenile-Onset
TERMINATED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Rheumatoid Arthritis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anakinra

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Kineret

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Informed consent by the patient
* Rheumatoid arthritis
* Previous methotrexate therapy with inadequate response

Exclusion Criteria

* Pregnancy
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Swedish Orphan Biovitrum

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Stefan Zeitler, MD

Role: STUDY_DIRECTOR

Swedish Orphan Biovitrum GmbH

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Swedish Orphan Biovitrum Investigational Site

Freiburg im Breisgau, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KIRA

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Patients With Rheumatoid Arthritis With Ongoing Treatment With Methotrexate
NCT00619905 COMPLETED PHASE1/PHASE2
Treatment of Refractory Adult-onset Still's Disease With Anakinra: a Randomized Study
NCT01033656 COMPLETED PHASE2
Treatment of Rheumatoid Arthritis With DMARDs: Predictors of Response
NCT03414502 RECRUITING PHASE3
A Multiple-dose Study of the Safety and Tolerability of REGN88(SAR153191) in Rheumatoid Arthritis Subjects
NCT01011959 COMPLETED PHASE1
Study Conducted in Subjects With Rheumatoid Arthritis Who Have Moderate to Severe Disease Activity Despite Methotrexate Therapy With or Without Other Non Biologic Disease Modifying Antirheumatic Drugs (DMARDs)for at Least 12 Weeks Prior to Screening
NCT01578850 COMPLETED PHASE4
Comparison of the Safety and Pharmacokinetics of Two SAR153191 (REGN88) Drug Products in Rheumatoid Arthritis Patients
NCT01328522 COMPLETED PHASE1
Assessment of the Effectiveness of IV and SC Abatacept (Orencia) Patient Alert Cards in Patients With Rheumatoid Arthritis in a Sample of EU Countries
NCT02632890 COMPLETED
Efficacy, Safety and Immunogenicity of Enerceptan Compared to Enbrel in Rheumatoid Arthritis
NCT03332719 COMPLETED PHASE3
REKinDLE: Registry With Enbrel® or Kineret® in a Database Using Longitudinal Evaluations
NCT00121056 COMPLETED
Good EULAR Response In Patients With Early Rheumatoid Arthritis
NCT01558089 COMPLETED
Clinical Study to Evaluate the Efficacy of Anakinra in Patients With Rheumatoid Arthritis and Diabetes
NCT02236481 TERMINATED PHASE4
Evaluating Kineret® (Anakinra) in Rheumatoid Arthritis (RA) Subjects Using aSelf-Reported Questionnaire
NCT00121043 COMPLETED PHASE4
A Study of the Safety and Pharmacokinetics of PRO283698 in Patients With Rheumatoid Arthritis
NCT00888745 COMPLETED PHASE1
Study of Etanercept in Subjects With Rheumatoid Arthritis Who Have Had an Inadequate Response to Adalimumab or Infliximab Plus Methotrexate
NCT01783015 TERMINATED PHASE4
Predicting the Response of Patients With Rheumatoid Arthritis to Treatment With Genetically Engineered Biological Drugs and Janus (JAK) Kinase Inhibitors
NCT06177405 COMPLETED
Study Evaluating Efficacy / Safety of Etanercept + Methotrexate Compared to Usual Treatment in Moderate RA Subjects
NCT00706797 TERMINATED PHASE4
Gene Expression Profiling in PBMCs as a Tool for Prediction of Anakinra Responsiveness in Rheumatoid Arthritis
NCT00213538 COMPLETED
Efficacy and Safety of Subcutaneous Versus Intravenous ACZ885 in Adult Patients With Established Rheumatoid Arthritis
NCT00505089 TERMINATED PHASE1/PHASE2
Etanercept (Enbrel) in Undifferentiated Spondyloarthritis
NCT01289730 UNKNOWN PHASE2
Drug Concentration, Immunogenicity, and Efficacy Study in Patients With Rheumatoid Arthritis Currently Treated With Etanercept, Adalimumab, or Infliximab
NCT01981473 COMPLETED
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Rheumatoid Arthritis (RA)
NCT02115750 COMPLETED PHASE3
Study Evaluating the Efficacy and Safety of Etanercept and Methotrexate in Japanese Subjects With Rheumatoid Arthritis
NCT00445770 COMPLETED PHASE3
Observational Trial With Enbrel
NCT00488475 COMPLETED
Study Comparing Etanercept in Combination With Methotrexate in Subjects With Rheumatoid Arthritis
NCT00565409 COMPLETED PHASE4
Enbrel Liquid Immunogenicity Protocol
NCT00249041 COMPLETED PHASE3